Core Viewpoint - 易明医药's stock closed at 23.35 yuan on August 15, experiencing a decline of 0.15 yuan or 0.64% from the previous trading day [1] Company Performance - For the first half of 2025, 易明医药 reported a revenue of 311 million yuan, representing a year-on-year decrease of 11.52% [1] - The net profit attributable to shareholders was 37.56 million yuan, down 5.27% year-on-year [1] - The company signed a compensation agreement with performance commitment parties, involving an amount of 14.43 million yuan [1] Market Activity - On August 15, the net inflow of main funds into 易明医药 was 19.95 million yuan, accounting for 0.49% of the circulating market value [1] - Over the past five days, the cumulative net inflow of main funds reached 199 million yuan, representing 4.89% of the circulating market value [1]